Uncovering metabolism in rhabdomyosarcoma

References

• Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 2009; 324(5930):1029-33; PMID:19460998; http://dx.doi.org/10.1126/science.1160809
   PubMed Web of Science ®Google Scholar
• Tennant DA, Durán RV, Boulahbel H, Gottlieb E. Metabolic transformation in cancer. Carcinogenesis. 2009; 30(8):1269-80; PMID:19321800; http://dx.doi.org/10.1093/carcin/bgp070
   PubMed Web of Science ®Google Scholar
• Levine AJ, Puzio-Kuter AM. The control of the metabolic switch in cancers by oncogenes and tumor suppressor genes. Science. 2010; 330(6009):1340-4; PMID:21127244; http://dx.doi.org/10.1126/science.1193494
   PubMed Web of Science ®Google Scholar
• Dang CV. Links between metabolism and cancer. Genes Dev. 2012; 26(9):877-90; PMID:22549953; http://dx.doi.org/10.1101/gad.189365.112
   PubMed Web of Science ®Google Scholar
• DeBerardinis RJ, Lum JJ, Hatzivassiliou G, Thompson CB. The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab. 2008; 7(1):11-20; PMID:18177721; http://dx.doi.org/10.1016/j.cmet.2007.10.002
   PubMed Web of Science ®Google Scholar
• Kroemer G, Pouyssegur J. Tumor cell metabolism: cancer's Achilles' heel. Cancer Cell. 2008; 13(6):472-82; PMID:18538731; http://dx.doi.org/10.1016/j.ccr.2008.05.005
   PubMed Web of Science ®Google Scholar
• Hsu PP, Sabatini DM. Cancer cell metabolism: Warburg and beyond. Cell. 2008; 134(5):703-7; PMID:18775299; http://dx.doi.org/10.1016/j.cell.2008.08.021
   PubMed Web of Science ®Google Scholar
• Muñoz-Pinedo C, El Mjiyad N, Ricci JE. Cancer metabolism: current perspectives and future directions. Cell Death Dis. 2012; 3:e248; PMID:22237205; http://dx.doi.org/10.1038/cddis.2011.123
   PubMed Web of Science ®Google Scholar
• Doherty JR, Cleveland JL. Targeting lactate metabolism for cancer therapeutics. J Clin Invest. 2013; 123(9):3685-92; PMID:23999443; http://dx.doi.org/10.1172/JCI69741
   PubMed Web of Science ®Google Scholar
• DeBerardinis RJ, Mancuso A, Daikhin E, Nissim I, Yudkoff M, Wehrli S, Thompson CB. Beyond aerobic glycolysis: transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis. Proc Natl Acad Sci U S A. 2007; 104(49):19345-50; PMID:18032601; http://dx.doi.org/10.1073/pnas.0709747104
   PubMed Web of Science ®Google Scholar
• Erickson JW, Cerione RA. Glutaminase: a hot spot for regulation of cancer cell metabolism? Oncotarget. 2010; 1(8):734-40; PMID:21234284
   PubMed Web of Science ®Google Scholar
• Wise DR, Thompson CB. Glutamine addiction: a new therapeutic target in cancer. Trends Biochem Sci. 2010; 35(8):427-33; PMID:20570523; http://dx.doi.org/10.1016/j.tibs.2010.05.003
   PubMed Web of Science ®Google Scholar
• Hensley CT, Wasti AT, DeBerardinis RJ. Glutamine and cancer: cell biology, physiology, and clinical opportunities. J Clin Invest. 2013; 123(9):3678-84; PMID:23999442; http://dx.doi.org/10.1172/JCI69600
   PubMed Web of Science ®Google Scholar
• Pandey PR, Liu W, Xing F, Fukuda K, Watabe K. Anti-cancer drugs targeting fatty acid synthase (FAS). Recent Pat Anticancer Drug Discov. 2012; 7(2):185-97; PMID:22338595; http://dx.doi.org/10.2174/157489212799972891
   PubMed Web of Science ®Google Scholar
• Flavin R, Peluso S, Nguyen PL, Loda M. Fatty acid synthase as a potential therapeutic target in cancer. Future Oncol. 2010; 6(4):551-62; PMID:20373869; http://dx.doi.org/10.2217/fon.10.11
   PubMed Web of Science ®Google Scholar
• Deavall DG, Martin EA, Horner JM, Roberts R. Drug-induced oxidative stress and toxicity. J Toxicol. 2012; 2012:645460; PMID:22919381
   PubMedGoogle Scholar
• Gorrini C, Harris IS, Mak TW. Modulation of oxidative stress as an anticancer strategy. Nat Rev Drug Discov. 2013; 12(12):931-47; PMID:24287781; http://dx.doi.org/10.1038/nrd4002
   PubMed Web of Science ®Google Scholar
• Trachootham D, Alexandre J, Huang P. Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach? Nat Rev Drug Discov. 2009; 8(7):579-91; PMID:19478820; http://dx.doi.org/10.1038/nrd2803
   PubMed Web of Science ®Google Scholar
• Zitka O, Skalickova S, Gumulec J, Masarik M, Adam V, Hubalek J, Trnkova L, Kruseova J, Eckschlager T, Kizek R. Redox status expressed as GSH:GSSG ratio as a marker for oxidative stress in paediatric tumour patients. Oncol Lett. 2012; 4(6):1247-53; PMID:23205122
   PubMed Web of Science ®Google Scholar
• Wolden SL, Alektiar KM. Sarcomas across the age spectrum. Semin Radiat Oncol. 2010; 20(1):45-51. 10.1016/j.semradonc.2009.09.003; PMID:19959030; http://dx.doi.org/10.1016/j.semradonc.2009.09.003
   PubMed Web of Science ®Google Scholar
• Dasgupta R, Rodeberg DA. Update on rhabdomyosarcoma. Semin Pediatr Surg. 2012; 21(1):68-78; PMID:22248972; http://dx.doi.org/10.1053/j.sempedsurg.2011.10.007
   PubMed Web of Science ®Google Scholar
• Parham DM, Alaggio R, Coffin CM. Myogenic tumors in children and adolescents. Pediatr Dev Pathol. 2012; 15(1 Suppl):211-38; PMID:22420729; http://dx.doi.org/10.2350/10-12-0953-PB.1
   PubMed Web of Science ®Google Scholar
• Ognjanovic S, Linabery AM, Charbonneau B, Ross JACP. Trends in childhood rhabdomyosarcoma incidence and survival in the United States, 1975-2005. Cancer. 2009; 115:4218-26; PMID:19536876; http://dx.doi.org/10.1002/cncr.24465
   PubMed Web of Science ®Google Scholar
• Hettmer S, Li Z, Billin AN, Barr FG, Cornelison DD, Ehrlich AR, Guttridge DC, Hayes-Jordan A, Helman LJ, Houghton PJ, et al. Rhabdomyosarcoma: current challenges and their implications for developing therapies. Cold Spring Harb Perspect Med. 2014; 4(11):a025650; PMID:25368019; http://dx.doi.org/10.1101/cshperspect.a025650
   PubMed Web of Science ®Google Scholar
• Keller C, Arenkiel BR, Coffin CM, El-Bardeesy N, DePinho RA, Capecchi MR. Alveolar rhabdomyosarcomas in conditional Pax3:Fkhr mice: cooperativity of Ink4a/ARF and Trp53 loss of function. Genes Dev. 2004; 18(21):2614-26 10.1101/gad.1244004; PMID:15489287; http://dx.doi.org/10.1101/gad.1244004
   PubMed Web of Science ®Google Scholar
• Hettmer S, Liu J, Miller CM, Lindsay MC, Sparks CA, Guertin DA, Bronson RT, Langenau DM, Wagers AJ. Sarcomas induced in discrete subsets of prospectively isolated skeletal muscle cells. Proc Natl Acad Sci U S A. 2011; 108(50):20002-7 10.1073/pnas.1111733108; PMID:22135462; http://dx.doi.org/10.1073/pnas.1111733108
   PubMed Web of Science ®Google Scholar
• Rubin BP, Nishijo K, Chen HI, Yi X, Schuetze DP, Pal R, Prajapati SI, Abraham J, Arenkiel BR, Chen QR, et al. Evidence for an unanticipated relationship between undifferentiated pleomorphic sarcoma and embryonal rhabdomyosarcoma. Cancer Cell. 2011; 19(2):177-91 10.1016/j.ccr.2010.12.023; PMID:21316601; http://dx.doi.org/10.1016/j.ccr.2010.12.023
   PubMed Web of Science ®Google Scholar
• Blum JM, Añó L, Li Z, Van Mater D, Bennett BD, Sachdeva M, Lagutina I, Zhang M, Mito JK, Dodd LG, et al. Distinct and overlapping sarcoma subtypes initiated from muscle stem and progenitor cells. Cell Rep. 2013; 5(4):933-40; PMID:24239359; http://dx.doi.org/10.1016/j.celrep.2013.10.020
   PubMed Web of Science ®Google Scholar
• Langenau DM, Keefe MD, Storer NY, Guyon JR, Kutok JL, Le X, Goessling W, Neuberg DS, Kunkel LM, Zon LI. Effects of RAS on the genesis of embryonal rhabdomyosarcoma. Genes Dev. 2007; 21:1382-95; PMID:17510286; http://dx.doi.org/10.1101/gad.1545007
   PubMed Web of Science ®Google Scholar
• Hatley ME, Tang W, Garcia MR, Finkelstein D, Millay DP, Liu N, Graff J, Galindo RL, Olson EN. A mouse model of rhabdomyosarcoma originating from the adipocyte lineage. Cancer Cell. 2012; 22(4):536-46; PMID:23079662; http://dx.doi.org/10.1016/j.ccr.2012.09.004
   PubMed Web of Science ®Google Scholar
• Dagher R, Helman L. Rhabdomyosarcoma: an overview. Oncologist. 1999; 4(1):34-44; PMID:10337369
   PubMedGoogle Scholar
• Parham DM, Barr FG. Classification of rhabdomyosarcoma and its molecular basis. Adv Anat Pathol. 2013; 20(6):387-97; PMID:24113309; http://dx.doi.org/10.1097/PAP.0b013e3182a92d0d
   PubMed Web of Science ®Google Scholar
• Shern JF, Chen L, Chmielecki J, Wei JS, Patidar R, Rosenberg M, Ambrogio L, Auclair D, Wang J, Song YK, et al. Comprehensive genomic analysis of rhabdomyosarcoma reveals a landscape of alterations affecting a common genetic axis in fusion-positive and fusion-negative tumors. Cancer Discov. 2014; 4(2):216-31; PMID:24436047; http://dx.doi.org/10.1158/2159-8290.CD-13-0639
   PubMed Web of Science ®Google Scholar
• Skapek SX, Anderson J, Barr FG, Bridge JA, Gastier-Foster JM, Parham DM, Rudzinski ER, Triche T, Hawkins DS. PAX-FOXO1 fusion status drives unfavorable outcome for children with rhabdomyosarcoma: a children's oncology group report. Pediatr Blood Cancer. 2013; 60(9):1411-7; PMID:23526739; http://dx.doi.org/10.1002/pbc.24532
   PubMed Web of Science ®Google Scholar
• Missiaglia E, Williamson D, Chisholm J, Wirapati P, Pierron G, Petel F, Concordet JP, Thway K, Oberlin O, Pritchard-Jones K, et al. PAX3/FOXO1 fusion gene status is the key prognostic molecular marker in rhabdomyosarcoma and significantly improves current risk stratification. J Clin Oncol. 2012; 30(14):1670-7; PMID:22454413; http://dx.doi.org/10.1200/JCO.2011.38.5591
   PubMed Web of Science ®Google Scholar
• Williamson D, Missiaglia E, de Reyniès A, Pierron G, Thuille B, Palenzuela G, Thway K, Orbach D, Laé M, Fréneaux P, et al. Fusion gene-negative alveolar rhabdomyosarcoma is clinically and molecularly indistinguishable from embryonal rhabdomyosarcoma. J Clin Oncol. 2010; 28(13):2151-8; PMID:20351326; http://dx.doi.org/10.1200/JCO.2009.26.3814
   PubMed Web of Science ®Google Scholar
• Mercado GE, Xia SJ, Zhang C, Ahn EH, Gustafson DM, Laé M, Ladanyi M, Barr FG. Identification of PAX3-FKHR-regulated genes differentially expressed between alveolar and embryonal rhabdomyosarcoma: focus on MYCN as a biologically relevant target. Genes Chromosomes Cancer. 2008; 47(6):510-20; PMID:18335505; http://dx.doi.org/10.1002/gcc.20554
   PubMed Web of Science ®Google Scholar
• Naini S, Etheridge KT, Adam SJ, Qualman SJ, Bentley RC, Counter CM, Linardic CM. Defining the cooperative genetic changes that temporally drive alveolar rhabdomyosarcoma. Cancer Res. 2008; 68(23):9583-8; PMID:19047133; http://dx.doi.org/10.1158/0008-5472.CAN-07-6178
   PubMed Web of Science ®Google Scholar
• Tonelli R, McIntyre A, Camerin C, Walters ZS, Di Leo K, Selfe J, Purgato S, Missiaglia E, Tortori A, Renshaw J, et al. Antitumor activity of sustained N-myc reduction in rhabdomyosarcomas and transcriptional block by antigene therapy. Clin Cancer Res. 2012; 18(3):796-807; PMID:22065083; http://dx.doi.org/10.1158/1078-0432.CCR-11-1981
   PubMed Web of Science ®Google Scholar
• Anderson J, Gordon A, McManus A, Shipley J, Pritchard-Jones K. Disruption of imprinted genes at chromosome region 11p15.5 in paediatric rhabdomyosarcoma. Neoplasia. 1999; 1(4):340-8; PMID:10935489; http://dx.doi.org/10.1038/sj.neo.7900052
   PubMedGoogle Scholar
• Thalhammer V, Lopez-Garcia LA, Herrero-Martin D, Hecker R, Laubscher D, Gierisch ME, Wachtel M, Bode P, Nanni P, Blank B, et al. PLK1 phosphorylates PAX3-FOXO1, the inhibition of which triggers regression of alveolar Rhabdomyosarcoma. Cancer Res. 2015; 75(1):98-110; PMID:25398439; http://dx.doi.org/10.1158/0008-5472.CAN-14-1246
   PubMed Web of Science ®Google Scholar
• Abraham J, Nuñez-Álvarez Y, Hettmer S, Carrió E, Chen HI, Nishijo K, Huang ET, Prajapati SI, Walker RL, Davis S, et al. Lineage of origin in rhabdomyosarcoma informs pharmacological response. Genes Dev. 2014; 28(14):1578-91; PMID:25030697; http://dx.doi.org/10.1101/gad.238733.114
   PubMed Web of Science ®Google Scholar
• Loupe JM, Miller PJ, Ruffin DR, Stark MW, Hollenbach AD. Inhibiting phosphorylation of the oncogenic PAX3-FOXO1 reduces alveolar rhabdomyosarcoma phenotypes identifying novel therapy options. Oncogenesis. 2015; 4:e145; PMID:25821947; http://dx.doi.org/10.1038/oncsis.2015.2
   PubMed Web of Science ®Google Scholar
• Scrable H, Cavenee W, Ghavimi F, Lovell M, Morgan K, Sapienza CCP. A model for embryonal rhabdomyosarcoma tumorigenesis that involves genome imprinting. Proc Natl Acad Sci U S A. 1989; 86:7480-4; PMID:2798419; http://dx.doi.org/10.1073/pnas.86.19.7480
   PubMed Web of Science ®Google Scholar
• Taylor JG, Cheuk AT, Tsang PS, Chung JY, Song YK, Desai K, Yu Y, Chen QR, Shah K, Youngblood V, et al. Identification of FGFR4-activating mutations in human rhabdomyosarcomas that promote metastasis in xenotransplanted models. J Clin Invest. 2009; 119:3395-407; PMID:19809159
   PubMed Web of Science ®Google Scholar
• Stratton MR, Fisher C, Gusterson BA, Cooper CS. Detection of point mutations in N-ras and K-ras genes of human embryonal rhabdomyosarcomas using oligonucleotide probes and the polymerase chain reaction. Cancer Res. 1989; 49(22):6324-7; PMID:2680062
   PubMed Web of Science ®Google Scholar
• Shukla N, Ameur N, Yilmaz I, Nafa K, Lau CY, Marchetti A, Borsu L, Barr FG, Ladanyi M. Oncogene mutation profiling of pediatric solid tumors reveals significant subsets of embryonal rhabdomyosarcoma and neuroblastoma with mutated genes in growth signaling pathways. Clin Cancer Res. 2012; 18(3):748-57; PMID:22142829; http://dx.doi.org/10.1158/1078-0432.CCR-11-2056
   PubMed Web of Science ®Google Scholar
• Taylor AC, Shu L, Danks MK, Poquette CA, Shetty S, Thayer MJ, Houghton PJ, Harris LC. P53 mutation and MDM2 amplification frequency in pediatric rhabdomyosarcoma tumors and cell lines. Med Pediatr Oncol. 2000; 35(2):96-103; PMID:10918230; http://dx.doi.org/10.1002/1096-911X(200008)35:2%3c96::AID-MPO2%3e3.0.CO;2-Z
   PubMedGoogle Scholar
• Xia SJ, Barr FG. Chromosome translocations in sarcomas and the emergence of oncogenic transcription factors. Eur J Cancer. 2005; 41(16):2513-27; PMID:16213703; http://dx.doi.org/10.1016/j.ejca.2005.08.003
   PubMed Web of Science ®Google Scholar
• Barr FG, Galili N, Holick J, Biegel JA, Rovera G, Emanuel BS. Rearrangement of the PAX3 paired box gene in the paediatric solid tumour alveolar rhabdomyosarcoma. Nat Genet. 1993; 3(2):113-7; PMID:8098985; http://dx.doi.org/10.1038/ng0293-113
   PubMed Web of Science ®Google Scholar
• Graf Finckenstein F, Shahbazian V, Davicioni E, Ren YX, Anderson MJ. PAX-FKHR function as pangenes by simultaneously inducing and inhibiting myogenesis. Oncogene. 2008; 27(14):2004-14 10.1038/sj.onc.1210835; PMID:17922034; http://dx.doi.org/10.1038/sj.onc.1210835
   PubMed Web of Science ®Google Scholar
• Keller C, Guttridge DC. Mechanisms of impaired differentiation in rhabdomyosarcoma. FEBS J. 2013; 280(17):4323-34; PMID:23822136; http://dx.doi.org/10.1111/febs.12421
   PubMed Web of Science ®Google Scholar
• Marshall AD, Grosveld GC. Alveolar rhabdomyosarcoma - The molecular drivers of PAX3/7-FOXO1-induced tumorigenesis. Skelet Muscle. 2012; 2(1):25; PMID:23206814; http://dx.doi.org/10.1186/2044-5040-2-25
   PubMed Web of Science ®Google Scholar
• Kikuchi K, Hettmer S, Aslam MI, Michalek JE, Laub W, Wilky BA, Loeb DM, Rubin BP, Wagers AJ, Keller C. Cell-cycle dependent expression of a translocation-mediated fusion oncogene mediates checkpoint adaptation in rhabdomyosarcoma. PLoS Genet. 2014; 10(1):e1004107; PMID:24453992; http://dx.doi.org/10.1371/journal.pgen.1004107
   PubMed Web of Science ®Google Scholar
• Armoni M, Quon MJ, Maor G, Avigad S, Shapiro DN, Harel C, Esposito D, Goshen Y, Yaniv I, Karnieli E. PAX3/forkhead homolog in rhabdomyosarcoma oncoprotein activates glucose transporter 4 gene expression in vivo and in vitro. J Clin Endocrinol Metab. 2002; 87(11):5312-24; PMID:12414908; http://dx.doi.org/10.1210/jc.2002-020318
   PubMed Web of Science ®Google Scholar
• Zhao Y, Butler EB, Tan M. Targeting cellular metabolism to improve cancer therapeutics. Cell Death Dis. 2013; 4:e532; PMID:23470539; http://dx.doi.org/10.1038/cddis.2013.60
   PubMed Web of Science ®Google Scholar
• Ramírez-Peinado S, Alcázar-Limones F, Lagares-Tena L, El Mjiyad N, Caro-Maldonado A, Tirado OM, Muñoz-Pinedo C. 2-deoxyglucose induces Noxa-dependent apoptosis in alveolar rhabdomyosarcoma. Cancer Res. 2011; 71(21):6796-806; PMID:21911456; http://dx.doi.org/10.1158/0008-5472.CAN-11-0759
   PubMed Web of Science ®Google Scholar
• Li HG, Wang Q, Li HM, Kumar S, Parker C, Slevin M, Kumar P. PAX3 and PAX3-FKHR promote rhabdomyosarcoma cell survival through downregulation of PTEN. Cancer Lett. 2007; 253(2):215-23; PMID:17350164; http://dx.doi.org/10.1016/j.canlet.2007.01.020
   PubMed Web of Science ®Google Scholar
• Li DM, Sun H. PTEN/MMAC1/TEP1 suppresses the tumorigenicity and induces G1 cell cycle arrest in human glioblastoma cells. Proc Natl Acad Sci U S A. 1998; 95(26):15406-11; PMID:9860981; http://dx.doi.org/10.1073/pnas.95.26.15406
   PubMed Web of Science ®Google Scholar
• Maehama T, Dixon JE. The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem. 1998; 273(22):13375-8; PMID:9593664; http://dx.doi.org/10.1074/jbc.273.22.13375
   PubMed Web of Science ®Google Scholar
• Jothi M, Nishijo K, Keller C, Mal AK. AKT and PAX3-FKHR cooperation enforces myogenic differentiation blockade in alveolar rhabdomyosarcoma cell. Cell Cycle. 2012; 11(5):895-908; PMID:22333587; http://dx.doi.org/10.4161/cc.11.5.19346
   PubMed Web of Science ®Google Scholar
• Van de Sande T, De Schrijver E, Heyns W, Verhoeven G, Swinnen JV. Role of the phosphatidylinositol 3′-kinase/PTEN/Akt kinase pathway in the overexpression of fatty acid synthase in LNCaP prostate cancer cells. Cancer Res. 2002; 62(3):642-6; PMID:11830512
   PubMed Web of Science ®Google Scholar
• Liu L, Wang YD, Wu J, Cui J, Chen T. Carnitine palmitoyltransferase 1A (CPT1A): a transcriptional target of PAX3-FKHR and mediates PAX3-FKHR-dependent motility in alveolar rhabdomyosarcoma cells. BMC Cancer. 2012; 12:154; PMID:22533991; http://dx.doi.org/10.1186/1471-2407-12-154
   PubMed Web of Science ®Google Scholar
• Edinger AL, Thompson CB. Akt maintains cell size and survival by increasing mTOR-dependent nutrient uptake. Mol Biol Cell. 2002; 13(7):2276-88; PMID:12134068; http://dx.doi.org/10.1091/mbc.01-12-0584
   PubMed Web of Science ®Google Scholar
• Elstrom RL, Bauer DE, Buzzai M, Karnauskas R, Harris MH, Plas DR, Zhuang H, Cinalli RM, Alavi A, Rudin CM, et al. Akt stimulates aerobic glycolysis in cancer cells. Cancer Res. 2004; 64(11):3892-9; PMID:15172999; http://dx.doi.org/10.1158/0008-5472.CAN-03-2904
   PubMed Web of Science ®Google Scholar
• Bauer DE, Hatzivassiliou G, Zhao F, Andreadis C, Thompson CB. ATP citrate lyase is an important component of cell growth and transformation. Oncogene. 2005; 24(41):6314-22; PMID:16007201; http://dx.doi.org/10.1038/sj.onc.1208773
   PubMed Web of Science ®Google Scholar
• Gingras AC, Raught B, Sonenberg N. Regulation of translation initiation by FRAP/mTOR. Genes Dev. 2001; 15(7):807-26; PMID:11297505; http://dx.doi.org/10.1101/gad.887201
   PubMed Web of Science ®Google Scholar
• Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer. 2003; 3(10):721-32; PMID:13130303; http://dx.doi.org/10.1038/nrc1187
   PubMed Web of Science ®Google Scholar
• De Luca A, Maiello MR, D'Alessio A, Pergameno M, Normanno N. The RAS/RAF/MEK/ERK and the PI3K/AKT signalling pathways: role in cancer pathogenesis and implications for therapeutic approaches. Expert Opin Ther Targets. 2012; 16 Suppl 2:S17-27; PMID:22443084; http://dx.doi.org/10.1517/14728222.2011.639361
   PubMed Web of Science ®Google Scholar
• Stephen AG, Esposito D, Bagni RK, McCormick F. Dragging ras back in the ring. Cancer Cell. 2014; 25(3):272-81; PMID:24651010; http://dx.doi.org/10.1016/j.ccr.2014.02.017
   PubMed Web of Science ®Google Scholar
• Adams JM, Harris AW, Pinkert CA, Corcoran LM, Alexander WS, Cory S, Palmiter RD, Brinster RL. The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice. Nature. 1985; 318(6046):533-8; PMID:3906410; http://dx.doi.org/10.1038/318533a0
   PubMed Web of Science ®Google Scholar
• Jain M, Arvanitis C, Chu K, Dewey W, Leonhardt E, Trinh M, Sundberg CD, Bishop JM, Felsher DW. Sustained loss of a neoplastic phenotype by brief inactivation of MYC. Science. 2002; 297(5578):102-4; PMID:12098700; http://dx.doi.org/10.1126/science.1071489
   PubMed Web of Science ®Google Scholar
• Dang CV. MYC on the path to cancer. Cell. 2012; 149(1):22-35; PMID:22464321; http://dx.doi.org/10.1016/j.cell.2012.03.003
   PubMed Web of Science ®Google Scholar
• Wysoczynski M, Shin DM, Kucia M, Ratajczak MZ. Selective upregulation of interleukin-8 by human rhabdomyosarcomas in response to hypoxia: therapeutic implications. Int J Cancer. 2010; 126(2):371-81; PMID:19588509; http://dx.doi.org/10.1002/ijc.24732
   PubMed Web of Science ®Google Scholar
• Gales D, Clark C, Manne U, Samuel T. The Chemokine CXCL8 in Carcinogenesis and Drug Response. ISRN Oncol. 2013; 2013:859154; PMID:24224100
   PubMedGoogle Scholar
• Murphy PM, Tiffany HL. Cloning of complementary DNA encoding a functional human interleukin-8 receptor. Science. 1991; 253(5025):1280-3; PMID:1891716; http://dx.doi.org/10.1126/science.1891716
   PubMed Web of Science ®Google Scholar
• Kilic M, Kasperczyk H, Fulda S, Debatin KM. Role of hypoxia inducible factor-1 alpha in modulation of apoptosis resistance. Oncogene. 2007; 26(14):2027-38; PMID:17043658; http://dx.doi.org/10.1038/sj.onc.1210008
   PubMed Web of Science ®Google Scholar
• Hinson AR, Jones R, Crose LE, Belyea BC, Barr FG, Linardic CM. Human rhabdomyosarcoma cell lines for rhabdomyosarcoma research: utility and pitfalls. Front Oncol. 2013; 3:183; PMID:23882450; http://dx.doi.org/10.3389/fonc.2013.00183
   PubMedGoogle Scholar
• Lei L, Mason S, Liu D, Huang Y, Marks C, Hickey R, Jovin IS, Pypaert M, Johnson RS, Giordano FJ. Hypoxia-inducible factor-dependent degeneration, failure, and malignant transformation of the heart in the absence of the von Hippel-Lindau protein. Mol Cell Biol. 2008; 28(11):3790-803; PMID:18285456; http://dx.doi.org/10.1128/MCB.01580-07
   PubMed Web of Science ®Google Scholar
• Guenther MK, Graab U, Fulda S. Synthetic lethal interaction between PI3K/Akt/mTOR and Ras/MEK/ERK pathway inhibition in rhabdomyosarcoma. Cancer Lett. 2013; 337(2):200-9; PMID:23684925; http://dx.doi.org/10.1016/j.canlet.2013.05.010
   PubMed Web of Science ®Google Scholar
• Kilic-Eren M, Boylu T, Tabor V. Targeting PI3K/Akt represses Hypoxia inducible factor-1alpha activation and sensitizes Rhabdomyosarcoma and Ewing's sarcoma cells for apoptosis. Cancer Cell Int. 2013; 13(1):36; PMID:23590596; http://dx.doi.org/10.1186/1475-2867-13-36
   PubMed Web of Science ®Google Scholar
• Wan X, Shen N, Mendoza A, Khanna C, Helman LJ. CCI-779 inhibits rhabdomyosarcoma xenograft growth by an antiangiogenic mechanism linked to the targeting of mTOR/Hif-1alpha/VEGF signaling. Neoplasia. 2006; 8(5):394-401; PMID:16790088; http://dx.doi.org/10.1593/neo.05820
   PubMed Web of Science ®Google Scholar
• Schwartzenberg-Bar-Yoseph F, Armoni M, Karnieli E. The tumor suppressor p53 down-regulates glucose transporters GLUT1 and GLUT4 gene expression. Cancer Res. 2004; 64(7):2627-33; PMID:15059920; http://dx.doi.org/10.1158/0008-5472.CAN-03-0846
   PubMed Web of Science ®Google Scholar
• Kawauchi K, Araki K, Tobiume K, Tanaka N. p53 regulates glucose metabolism through an IKK-NF-kappaB pathway and inhibits cell transformation. Nat Cell Biol. 2008; 10(5):611-8; PMID:18391940; http://dx.doi.org/10.1038/ncb1724
   PubMed Web of Science ®Google Scholar
• Pilkis SJ, El-Maghrabi MR, Pilkis J, Claus TH, Cumming DA. Fructose 2,6-bisphosphate. A new activator of phosphofructokinase. J Biol Chem. 1981; 256(7):3171-4; PMID:6451625
   PubMed Web of Science ®Google Scholar
• Kondoh H, Lleonart ME, Gil J, Wang J, Degan P, Peters G, Martinez D, Carnero A, Beach D. Glycolytic enzymes can modulate cellular life span. Cancer Res. 2005; 65(1):177-85; PMID:15665293
   PubMed Web of Science ®Google Scholar
• Bensaad K, Tsuruta A, Selak MA, Vidal MN, Nakano K, Bartrons R, Gottlieb E, Vousden KH. TIGAR, a p53-inducible regulator of glycolysis and apoptosis. Cell. 2006; 126(1):107-20; PMID:16839880; http://dx.doi.org/10.1016/j.cell.2006.05.036
   PubMed Web of Science ®Google Scholar
• Cairns RA, Harris IS, Mak TW. Regulation of cancer cell metabolism. Nat Rev Cancer. 2011; 11(2):85-95; PMID:21258394; http://dx.doi.org/10.1038/nrc2981
   PubMed Web of Science ®Google Scholar
• Chen X, Stewart E, Shelat AA, Qu C, Bahrami A, Hatley M, Wu G, Bradley C, McEvoy J, Pappo A, et al. Targeting oxidative stress in embryonal rhabdomyosarcoma. Cancer Cell. 2013; 24(6):710-24; PMID:24332040; http://dx.doi.org/10.1016/j.ccr.2013.11.002
   PubMed Web of Science ®Google Scholar
• Ito S, Fukusato T, Nemoto T, Sekihara H, Seyama Y, Kubota S. Coexpression of glucose transporter 1 and matrix metalloproteinase-2 in human cancers. J Natl Cancer Inst. 2002; 94(14):1080-91; PMID:12122099; http://dx.doi.org/10.1093/jnci/94.14.1080
   PubMed Web of Science ®Google Scholar
• Matoba S, Kang JG, Patino WD, Wragg A, Boehm M, Gavrilova O, Hurley PJ, Bunz F, Hwang PM. p53 regulates mitochondrial respiration. Science. 2006; 312(5780):1650-3; PMID:16728594; http://dx.doi.org/10.1126/science.1126863
   PubMed Web of Science ®Google Scholar
• Cheung EC, Vousden KH. The role of p53 in glucose metabolism. Curr Opin Cell Biol. 2010; 22(2):186-91; PMID:20061129; http://dx.doi.org/10.1016/j.ceb.2009.12.006
   PubMed Web of Science ®Google Scholar
• Puzio-Kuter AM. The Role of p53 in Metabolic Regulation. Genes Cancer. 2011; 2(4):385-91; PMID:21779507; http://dx.doi.org/10.1177/1947601911409738
   PubMedGoogle Scholar
• Berkers CR, Maddocks OD, Cheung EC, Mor I, Vousden KH. Metabolic Regulation by p53 Family Members. Cell Metab. 2013; 18(5):617-33; PMID:23954639; http://dx.doi.org/10.1016/j.cmet.2013.06.019
   PubMed Web of Science ®Google Scholar
• Contractor T, Harris CR. p53 negatively regulates transcription of the pyruvate dehydrogenase kinase Pdk2. Cancer Res. 2012; 72(2):560-7; PMID:22123926; http://dx.doi.org/10.1158/0008-5472.CAN-11-1215
   PubMed Web of Science ®Google Scholar
• Vousden KH, Ryan KM. p53 and metabolism. Nat Rev Cancer. 2009; 9(10):691-700; PMID:19759539; http://dx.doi.org/10.1038/nrc2715
   PubMed Web of Science ®Google Scholar
• Suzuki S, Tanaka T, Poyurovsky MV, Nagano H, Mayama T, Ohkubo S, Lokshin M, Hosokawa H, Nakayama T, Suzuki Y, et al. Phosphate-activated glutaminase (GLS2), a p53-inducible regulator of glutamine metabolism and reactive oxygen species. Proc Natl Acad Sci U S A. 2010; 107(16):7461-6; PMID:20351271; http://dx.doi.org/10.1073/pnas.1002459107
   PubMed Web of Science ®Google Scholar
• Zhang M, Linardic CM, Kirsch DG. RAS and ROS in rhabdomyosarcoma. Cancer Cell. 2013; 24(6):689-91; PMID:24332036; http://dx.doi.org/10.1016/j.ccr.2013.11.015
   PubMed Web of Science ®Google Scholar
• Weinberg F, Hamanaka R, Wheaton WW, Weinberg S, Joseph J, Lopez M, Kalyanaraman B, Mutlu GM, Budinger GR, Chandel NS. Mitochondrial metabolism and ROS generation are essential for Kras-mediated tumorigenicity. Proc Natl Acad Sci U S A 2010; 107(19):8788-93; PMID:20421486; http://dx.doi.org/10.1073/pnas.1003428107
   PubMed Web of Science ®Google Scholar
• SMYD1 and G6PD modulation are critical events for miR-206-mediated differentiation of rhabdomyosarcoma. Coda DM, Lingua MF, Morena D, Foglizzo V, Bersani F, Ala U, Ponzetto C, Taulli R. Cell Cycle 2015; 14(9):1389-402; http://dx.doi.org/10.1080/15384101.2015.1005993.
   Google Scholar
• Zhang W, Trachootham D, Liu J, Chen G, Pelicano H, Garcia-Prieto C, Lu W, Burger JA, Croce CM, Plunkett W, et al. Stromal control of cystine metabolism promotes cancer cell survival in chronic lymphocytic leukaemia. Nat Cell Biol. 2012; 14(3):276-86; PMID:22344033; http://dx.doi.org/10.1038/ncb2432
   PubMed Web of Science ®Google Scholar
• Ishimoto T, Nagano O, Yae T, Tamada M, Motohara T, Oshima H, Oshima M, Ikeda T, Asaba R, Yagi H, et al. CD44 variant regulates redox status in cancer cells by stabilizing the xCT subunit of system xc(-) and thereby promotes tumor growth. Cancer Cell. 2011; 19(3):387-400; PMID:21397861; http://dx.doi.org/10.1016/j.ccr.2011.01.038
   PubMed Web of Science ®Google Scholar
• Jain M, Nilsson R, Sharma S, Madhusudhan N, Kitami T, Souza AL, Kafri R, Kirschner MW, Clish CB, Mootha VK. Metabolite profiling identifies a key role for glycine in rapid cancer cell proliferation. Science. 2012; 336(6084):1040-4; PMID:22628656; http://dx.doi.org/10.1126/science.1218595
   PubMed Web of Science ®Google Scholar
• Deberardinis RJ, Sayed N, Ditsworth D, Thompson CB. Brick by brick: metabolism and tumor cell growth. Curr Opin Genet Dev. 2008; 18(1):54-61; PMID:18387799; http://dx.doi.org/10.1016/j.gde.2008.02.003
   PubMed Web of Science ®Google Scholar
• Kalhan SC, Hanson RW. Resurgence of serine: an often neglected but indispensable amino Acid. J Biol Chem. 2012; 287(24):19786-91; PMID:22566694; http://dx.doi.org/10.1074/jbc.R112.357194
   PubMed Web of Science ®Google Scholar
• Amelio I, Cutruzzolá F, Antonov A, Agostini M, Melino G. Serine and glycine metabolism in cancer. Trends Biochem Sci. 2014; 39(4):191-8; PMID:24657017
   PubMed Web of Science ®Google Scholar
• Maddocks OD, Berkers CR, Mason SM, Zheng L, Blyth K, Gottlieb E, Vousden KH. Serine starvation induces stress and p53-dependent metabolic remodelling in cancer cells. Nature. 2013; 493(7433):542-6; PMID:23242140; http://dx.doi.org/10.1038/nature11743
   PubMed Web of Science ®Google Scholar
• Amelio I, Markert EK, Rufini A, Antonov AV, Sayan BS, Tucci P, Agostini M, Mineo TC, Levine AJ, Melino G. p73 regulates serine biosynthesis in cancer. Oncogene 2014; 33(42):5039-46; http://dx.doi.org.10.1038/onc.2013.456.
   Google Scholar
• Du W, Jiang P, Mancuso A, Stonestrom A, Brewer MD, Minn AJ, Mak TW, Wu M, Yang X. TAp73 enhances the pentose phosphate pathway and supports cell proliferation. Nat Cell Biol. 2013; 15(8):991-1000; PMID:23811687; http://dx.doi.org/10.1038/ncb2789
   PubMed Web of Science ®Google Scholar
• Jiang P, Du W, Yang X. A critical role of glucose-6-phosphate dehydrogenase in TAp73-mediated cell proliferation. Cell Cycle. 2013; 12(24):3720-6; PMID:24270845; http://dx.doi.org/10.4161/cc.27267
   PubMed Web of Science ®Google Scholar
• Cam H, Griesmann H, Beitzinger M, Hofmann L, Beinoraviciute-Kellner R, Sauer M, Hüttinger-Kirchhof N, Oswald C, Friedl P, Gattenlöhner S, et al. p53 family members in myogenic differentiation and rhabdomyosarcoma development. Cancer Cell. 2006; 10(4):281-93; PMID:17045206; http://dx.doi.org/10.1016/j.ccr.2006.08.024
   PubMed Web of Science ®Google Scholar
• Sporn MB, Liby KT. NRF2 and cancer: the good, the bad and the importance of context. Nat Rev Cancer. 2012; 12(8):564-71; PMID:22810811; http://dx.doi.org/10.1038/nrc3278
   PubMed Web of Science ®Google Scholar
• Je EM, An CH, Yoo NJ, Lee SH. Mutational and expressional analyses of NRF2 and KEAP1 in sarcomas. Tumori. 2012; 98(4):510-5; PMID:23052169
   PubMed Web of Science ®Google Scholar
• Hu W, Zhang C, Wu R, Sun Y, Levine A, Feng Z. Glutaminase 2, a novel p53 target gene regulating energy metabolism and antioxidant function. Proc Natl Acad Sci U S A. 2010; 107(16):7455-60; PMID:20378837; http://dx.doi.org/10.1073/pnas.1001006107
   PubMed Web of Science ®Google Scholar
• Budanov AV, Sablina AA, Feinstein E, Koonin EV, Chumakov PM. Regeneration of peroxiredoxins by p53-regulated sestrins, homologs of bacterial AhpD. Science. 2004; 304(5670):596-600; PMID:15105503; http://dx.doi.org/10.1126/science.1095569
   PubMed Web of Science ®Google Scholar
• Cano CE, Gommeaux J, Pietri S, Culcasi M, Garcia S, Seux M, Barelier S, Vasseur S, Spoto RP, Pébusque MJ, et al. Tumor protein 53-induced nuclear protein 1 is a major mediator of p53 antioxidant function. Cancer Res. 2009; 69(1):219-26; PMID:19118006; http://dx.doi.org/10.1158/0008-5472.CAN-08-2320
   PubMed Web of Science ®Google Scholar
• Tan M, Li S, Swaroop M, Guan K, Oberley LW, Sun Y. Transcriptional activation of the human glutathione peroxidase promoter by p53. J Biol Chem. 1999; 274(17):12061-6; PMID:10207030; http://dx.doi.org/10.1074/jbc.274.17.12061
   PubMed Web of Science ®Google Scholar
• Yoon KA, Nakamura Y, Arakawa H. Identification of ALDH4 as a p53-inducible gene and its protective role in cellular stresses. J Hum Genet. 2004; 49(3):134-40; PMID:14986171; http://dx.doi.org/10.1007/s10038-003-0122-3
   PubMed Web of Science ®Google Scholar
• Chen W, Sun Z, Wang XJ, Jiang T, Huang Z, Fang D, Zhang DD. Direct interaction between Nrf2 and p21(Cip1/WAF1) upregulates the Nrf2-mediated antioxidant response. Mol Cell. 2009; 34(6):663-73; PMID:19560419; http://dx.doi.org/10.1016/j.molcel.2009.04.029
   PubMed Web of Science ®Google Scholar
• Rotblat B, Melino G, Knight RA. NRF2 and p53: Januses in cancer? Oncotarget. 2012; 3(11):1272-83; PMID:23174755
   PubMed Web of Science ®Google Scholar
• Swanton C. Intratumor heterogeneity: evolution through space and time. Cancer Res. 2012; 72(19):4875-82; PMID:23002210; http://dx.doi.org/10.1158/0008-5472.CAN-12-2217
   PubMed Web of Science ®Google Scholar
• Almendro V, Marusyk A, Polyak K. Cellular heterogeneity and molecular evolution in cancer. Annu Rev Pathol. 2013; 8:277-302; PMID:23092187; http://dx.doi.org/10.1146/annurev-pathol-020712-163923
   PubMed Web of Science ®Google Scholar
• Marusyk A, Polyak K. Tumor heterogeneity: causes and consequences. Biochim Biophys Acta. 2010; 1805(1):105-17; PMID:19931353
   PubMed Web of Science ®Google Scholar
• Chen L, Shern JF, Wei JS, Yohe ME, Song YK, Hurd L, Liao H, Catchpoole D, Skapek SX, Barr FG, et al. Clonality and evolutionary history of rhabdomyosarcoma. PLoS Genet. 2015; 11(3):e1005075; PMID:25768946; http://dx.doi.org/10.1371/journal.pgen.1005075
   PubMed Web of Science ®Google Scholar
• Ignatius MS, Chen E, Elpek NM, Fuller AZ, Tenente IM, Clagg R, Liu S, Blackburn JS, Linardic CM, Rosenberg AE, et al. In vivo imaging of tumor-propagating cells, regional tumor heterogeneity, and dynamic cell movements in embryonal rhabdomyosarcoma. Cancer Cell. 2012; 21(5):680-93; PMID:22624717; http://dx.doi.org/10.1016/j.ccr.2012.03.043
   PubMed Web of Science ®Google Scholar
• Blackburn JS, Langenau DM. Zebrafish as a model to assess cancer heterogeneity, progression and relapse. Dis Model Mech. 2014; 7(7):755-62; PMID:24973745; http://dx.doi.org/10.1242/dmm.015842
   PubMed Web of Science ®Google Scholar
• Pavlides S, Whitaker-Menezes D, Castello-Cros R, Flomenberg N, Witkiewicz AK, Frank PG, Casimiro MC, Wang C, Fortina P, Addya S, et al. The reverse Warburg effect: aerobic glycolysis in cancer associated fibroblasts and the tumor stroma. Cell Cycle. 2009; 8(23):3984-4001; PMID:19923890; http://dx.doi.org/10.4161/cc.8.23.10238
   PubMed Web of Science ®Google Scholar
• Li G, Kikuchi K, Radka M, Abraham J, Rubin BP, Keller C. IL-4 receptor blockade abrogates satellite cell: rhabdomyosarcoma fusion and prevents tumor establishment. Stem Cells. 2013; 31(11):2304-12. PMID:23897781; http://dx.doi.org/10.1002/stem.1491
   PubMed Web of Science ®Google Scholar
• Van Gaal JC, De Bont ES, Kaal SE, Versleijen-Jonkers Y, van der Graaf WT. Building the bridge between rhabdomyosarcoma in children, adolescents and young adults: The road ahead. Crit Rev Oncol Hematol. 2011; 82(3):259-79; PMID:21802959
   PubMed Web of Science ®Google Scholar
• Wachtel M, Schäfer BW. Targets for cancer therapy in childhood sarcomas. Cancer Treat Rev. 2010; 36(4):318-27. PMID:20223596; http://dx.doi.org/10.1016/j.ctrv.2010.02.007
   PubMed Web of Science ®Google Scholar
• Crose LE, Linardic CM. Receptor tyrosine kinases as therapeutic targets in rhabdomyosarcoma. Sarcoma. 2011; 2011:756982. PMID:21253475; http://dx.doi.org/10.1155/2011/756982
   PubMedGoogle Scholar
• Ferguson M, Hingorani P, Gupta AA. Emerging molecular-targeted therapies in early-phase clinical trials and preclinical models. Am Soc Clin Oncol Educ Book. 2013:420-4. PMID:23714564; http://dx.doi.org/10.1200/EdBook_AM.2013.33.420
   PubMedGoogle Scholar
• Kalloniatis M, Marc RE, Murry RF. Amino acid signatures in the primate retina. J Neurosci. 1996; 16(21):6807-29; PMID:8824321
   PubMed Web of Science ®Google Scholar
• Marc RE, Murry RF, Basinger SF. Pattern recognition of amino acid signatures in retinal neurons. J Neurosci. 1995; 15(7 Pt 2):5106-29; PMID:7623139
   PubMed Web of Science ®Google Scholar
• Marc RE, Cameron D. A molecular phenotype atlas of the zebrafish retina. J Neurocytol. 2001; 30(7):593-654; PMID:12118163; http://dx.doi.org/10.1023/A:1016516818393
   PubMedGoogle Scholar
• Marc RE, Jones BW. Molecular phenotyping of retinal ganglion cells. J Neurosci. 2002; 22(2):413-27; PMID:11784786
   PubMed Web of Science ®Google Scholar
• Marc RE, Jones BW, Watt CB, Strettoi E. Neural remodeling in retinal degeneration. Prog Retin Eye Res. 2003; 22(5):607-55; PMID:12892644; http://dx.doi.org/10.1016/S1350-9462(03)00039-9
   PubMed Web of Science ®Google Scholar
• Weigel B, Malempati S, Reid JM, Voss SD, Cho SY, Chen HX, Krailo M, Villaluna D, Adamson PC, Blaney SM. Phase 2 trial of cixutumumab in children, adolescents, and young adults with refractory solid tumors: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2014; 61(3):452-6. PMID:23956055; http://dx.doi.org/10.1002/pbc.24605
   PubMed Web of Science ®Google Scholar
• Schöffski P, Adkins D, Blay JY, Gil T, Elias AD, Rutkowski P, Pennock GK, Youssoufian H, Gelderblom H, Willey R, et al. An open-label, phase 2 study evaluating the efficacy and safety of the anti-IGF-1R antibody cixutumumab in patients with previously treated advanced or metastatic soft-tissue sarcoma or Ewing family of tumours. Eur J Cancer. 2013; 49(15):3219-28. PMID:23835252; http://dx.doi.org/10.1016/j.ejca.2013.06.010
   PubMed Web of Science ®Google Scholar
• Pappo AS, Vassal G, Crowley JJ, Bolejack V, Hogendoorn PC, Chugh R, Ladanyi M, Grippo JF, Dall G, Staddon AP, et al. A phase 2 trial of R1507, a monoclonal antibody to the insulin-like growth factor-1 receptor (IGF-1R), in patients with recurrent or refractory rhabdomyosarcoma, osteosarcoma, synovial sarcoma, and other soft tissue sarcomas: results of a Sarcoma Alliance for Research Through Collaboration study. Cancer. 2014; 120(16):2448-56. PMID:24797726; http://dx.doi.org/10.1002/cncr.28728
   PubMed Web of Science ®Google Scholar
• Bagatell R, Norris R, Ingle AM, Ahern C, Voss S, Fox E, Little AR, Weigel BJ, Adamson PC, Blaney S. Phase 1 trial of temsirolimus in combination with irinotecan and temozolomide in children, adolescents and young adults with relapsed or refractory solid tumors: a Children's Oncology Group Study. Pediatr Blood Cancer. 2014; 61(5):833-9. PMID:24249672; http://dx.doi.org/10.1002/pbc.24874
   PubMed Web of Science ®Google Scholar
• Wagner LM, Fouladi M, Ahmed A, Krailo MD, Weigel B, DuBois SG, Doyle LA, Chen H, Blaney SM. Phase II study of cixutumumab in combination with temsirolimus in pediatric patients and young adults with recurrent or refractory sarcoma: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2015; 62(3):440-4. PMID:25446280; http://dx.doi.org/10.1002/pbc.25334
   PubMed Web of Science ®Google Scholar
• Chugh R, Wathen JK, Maki RG, Benjamin RS, Patel SR, Meyers PA, Priebat DA, Reinke DK, Thomas DG, Keohan ML, et al. Phase II multicenter trial of imatinib in 10 histologic subtypes of sarcoma using a bayesian hierarchical statistical model. J Clin Oncol. 2009; 27(19):3148-53. PMID:19451433; http://dx.doi.org/10.1200/JCO.2008.20.5054
   PubMed Web of Science ®Google Scholar
• Baruchel S, Pappo A, Krailo M, Baker KS, Wu B, Villaluna D, Lee-Scott M, Adamson PC, Blaney SM. A phase 2 trial of trabectedin in children with recurrent rhabdomyosarcoma, Ewing sarcoma and non-rhabdomyosarcoma soft tissue sarcomas: a report from the Children's Oncology Group. Eur J Cancer. 2012; 48(4):579-85. PMID:22088484; http://dx.doi.org/10.1016/j.ejca.2011.09.027
   PubMed Web of Science ®Google Scholar
• Warwick AB, Malempati S, Krailo M, Melemed A, Gorlick R, Ames MM, Safgren SL, Adamson PC, Blaney SM. Phase 2 trial of pemetrexed in children and adolescents with refractory solid tumors: a Children's Oncology Group study. Pediatr Blood Cancer. 2013; 60(2):237-41. PMID:22745043; http://dx.doi.org/10.1002/pbc.24244
   PubMed Web of Science ®Google Scholar